Global Artificial Intelligence-driven Drug Development Market Growth (Status and Outlook) 2023-2029

Global Artificial Intelligence-driven Drug Development Market Growth (Status and Outlook) 2023-2029

The global Artificial Intelligence-driven Drug Development market size is projected to grow from US$ 1336.6 million in 2022 to US$ 9237.4 million in 2029; it is expected to grow at a CAGR of 31.8% from 2023 to 2029.

United States market for Artificial Intelligence-driven Drug Development is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Artificial Intelligence-driven Drug Development is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Artificial Intelligence-driven Drug Development is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Artificial Intelligence-driven Drug Development players cover IBM, Exscientia, Google(Alphabet), Microsoft, Atomwise, Schrodinger, Aitia, Insilico Medicine and NVIDIA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Artificial intelligence (AI) has the potential to revolutionize the drug discovery process,

offering improved efficiency, accuracy, and speed.



LPI (LP Information)' newest research report, the “Artificial Intelligence-driven Drug Development Industry Forecast” looks at past sales and reviews total world Artificial Intelligence-driven Drug Development sales in 2022, providing a comprehensive analysis by region and market sector of projected Artificial Intelligence-driven Drug Development sales for 2023 through 2029. With Artificial Intelligence-driven Drug Development sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Artificial Intelligence-driven Drug Development industry.

This Insight Report provides a comprehensive analysis of the global Artificial Intelligence-driven Drug Development landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Artificial Intelligence-driven Drug Development portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Artificial Intelligence-driven Drug Development market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Artificial Intelligence-driven Drug Development and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Artificial Intelligence-driven Drug Development.

This report presents a comprehensive overview, market shares, and growth opportunities of Artificial Intelligence-driven Drug Development market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Hardware
Software
Service

Segmentation by application
Early Drug Discovery
Preclinical Phase
Clinical Phase
Regulatory Approval

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
IBM
Exscientia
Google(Alphabet)
Microsoft
Atomwise
Schrodinger
Aitia
Insilico Medicine
NVIDIA
XtalPi
BPGbio
Owkin
CytoReason
Deep Genomics
Cloud Pharmaceuticals
BenevolentAI
Cyclica
Verge Genomics
Valo Health
Envisagenics
Euretos
BioAge Labs
Iktos
BioSymetrics
Evaxion Biotech
Aria Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.